This site complies with the HONcode standard for trustworthy health information: verify here.
Oncology Clinical News
Black Patients Miss Out on Promising Cancer Drugs
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer
(Markets Insider) Sept 18, 2018 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of erdafitinib for the treatment of patients with locally advanced or metastatic urothelial cancer (UC) and certain fibroblast growth factor receptor (FGFR) genetic alterations whose tumors have progressed after prior chemotherapy. Erdafitinib is an investigational, once-daily, oral pan-FGFR inhibitor that received Breakthrough Therapy Designation from the FDA in March 2018.
Read full article.
Biopharmaceutical Company, Executives Charged With Misleading Investors About Cancer Drug
This site complies with the HONcode standard for trustworthy health information: verify here.